Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products Questions and Answers: Guidance for Industry Q&A - FDA Guidance Document

Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products Questions and Answers: Guidance for Industry Q&A - FDA Guidance Document | Global Key Solutions